COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03599622
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : June 11, 2020
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
This is an investigational study, also known as LATTICE-CD, of the experimental medication BMS-986165 in participants with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Condition or disease Intervention/treatment Phase
Granulomatous Colitis Crohn's Disease Crohn's Enteritis Granulomatous Enteritis Drug: BMS-986165 Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's Disease
Actual Study Start Date : June 29, 2018
Estimated Primary Completion Date : December 26, 2022
Estimated Study Completion Date : December 25, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: BMS-986165 Dose 1 Drug: BMS-986165
oral administration

Experimental: BMS-986165 Dose 2 Drug: BMS-986165
oral administration

Placebo Comparator: Placebo Other: Placebo
oral administration

Primary Outcome Measures :
  1. Proportion of subjects achieving clinical remission [ Time Frame: 12 weeks ]
    Clinical remission defined by Crohn's Disease Activity Index (CDAI)

  2. Proportion of subjects achieving endoscopic response [ Time Frame: 12 weeks ]
    Endoscopic response defined by Simple Endoscopic Score for Crohn's Disease (SES-CD)

Secondary Outcome Measures :
  1. Proportion of participants who achieve endoscopic remission [ Time Frame: 12 weeks ]
  2. Proportion of participants who achieve a clinical response [ Time Frame: 12 weeks ]
  3. Proportion of Participants maintaining deep remission [ Time Frame: 12 weeks ]
  4. Proportion of participants who achieve PRO2 remission [ Time Frame: 12 weeks ]
  5. Changes from baseline in SES-CD [ Time Frame: 12 Weeks ]
  6. Proportion of participants achieving endoscopic normalization [ Time Frame: 12 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

Documented diagnosis of Crohn's Disease for at least 3 months

Exclusion Criteria:

Severe or fulminant colitis that is likely to require surgery or hospitalization Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease Other protocol defined inclusion/exclusion criteria could apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03599622

Layout table for location contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Contact: First line of the email MUST contain NCT # and Site #.

Show Show 306 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT03599622    
Other Study ID Numbers: IM011-023
2017-001976-48 ( EudraCT Number )
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Dermatologic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action